Stay updated on Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page shows a minor revision update from v3.3.3 to v3.3.4 with no changes to the clinical study details. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-17T00:44:35.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    The Locations section now includes a new Illinois site. The HHS Vulnerability Disclosure link was removed and the page revision updated to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-19T12:59:34.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    Revision: v3.3.2 has been added and Revision: v3.3.1 has been removed.
    Difference
    0.0%
    Check dated 2025-11-28T04:27:59.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    Revision tag updated from v3.2.0 to v3.3.1; no changes to trial details, outcomes, eligibility criteria, or locations.
    Difference
    0.0%
    Check dated 2025-11-21T02:11:18.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    The funding status notice about government operations was removed from the page. This notice previously warned that updates may be delayed due to appropriations.
    Difference
    0.2%
    Check dated 2025-11-13T22:49:41.000Z thumbnail image
  8. Check
    81 days ago
    Change Detected
    Summary
    No additions or deletions affecting core page content were detected; the study overview and eligibility details appear unchanged.
    Difference
    0.2%
    Check dated 2025-10-30T15:23:01.000Z thumbnail image

Stay in the know with updates to Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.